Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC

About this episode

Jorge Nieva, MD discusses the management of toxicity in patients with advanced EGFR-mutated NSCLC and the importance of shared decision making.

Combination regimens improve survival in advanced EGFR-mutated NSCLC, but they also increase toxicity. Jorge Nieva, MD, shares how he talks with patients about potential adverse events. Hedescribes the options available for prophylaxis and how he treats the toxicities that do arise.

People in this episode

Host: Oncology News Central

Guest: Jorge Nieva, MD

Topics covered

• shared decision making
• toxicity management
• EGFR-mutated NSCLC
• patient communication
• adverse events
• prophylaxis options

Keywords

• EGFR
• NSCLC
• toxicity
• adverse events
• prophylaxis
• patient communication
• survival
• combination regimens

Mentioned in this episode

Organizations: Oncology News Central

Books & works: EGFR- Mutated Advanced NSCLC

More episodes of Oncology News Central Peer-Spectives

• “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · April 29, 2026 · 11 min
• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · April 17, 2026 · 12 min
• Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · April 2, 2026 · 14 min
• “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · December 18, 2025 · 15 min
• “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · December 16, 2025 · 13 min